PharmaTher Holdings Ltd. News Releases

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

Tue, 21 Jul 2026 08:00:00 -0400

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experiencePursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundationKetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchiseToronto, Ontario--(Newsfile Corp. - July 21, 2026) -...

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

Wed, 15 Jul 2026 08:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, today provided a corporate update outlining its strategic focus on personalized medicines, specifically peptides and psychedelics.PharmaTher believes peptides and psychedelics are gaining strong momentum and plans to capitalize on this opportunity using its MEDBOTX™ 3D-printing platform and...

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

Wed, 27 May 2026 08:00:00 -0400

MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formatsPotential U.S. peptide reclassification and possible inclusion of select peptides on the Section 503A Bulks List could create a timely opportunity for MEDBOTX™ in compounding pharmacies, hospitals and personalized medicine settingsToronto, Ontario--(Newsfile Corp. - May 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF)...

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

Wed, 13 May 2026 10:11:00 -0400

Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting further evaluation of Sairiyo's patented, orally bioavailable PD-001 cepharanthine formulation for Hantavirus Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 49% owned by PharmaTher and 51% owned by...

PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

Tue, 21 Apr 2026 08:00:00 -0400

Company believes supportive U.S. policy momentum may strengthen the strategic value of its ketamine patch, KetaVault™ platform, retained ketamine programs, and prior FDA-approved ketamine ANDA transactionToronto, Ontario--(Newsfile Corp. - April 21, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that it believes the recent U.S. executive order, "Accelerating Medical Treatments for Serious Mental...

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

Mon, 20 Apr 2026 08:00:00 -0400

U.S. regulatory momentum in psychedelics and peptides could open new commercial opportunities for PharmaTher's PatchPrint™ automated manufacturing platform and PharmaPatch™ product platform as an attractive solution for compounding pharmacies, hospitals, research institutions, and commercial partnersToronto, Ontario--(Newsfile Corp. - April 20, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle...

PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

Thu, 16 Apr 2026 08:00:00 -0400

Anticipated peptide reclassification could expand the addressable market for PharmaTher's PharmaPatch™ product strategy and PatchPrint™ manufacturing platform, strengthening its position in next-generation peptide deliveryToronto, Ontario--(Newsfile Corp. - April 16, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies and peptide-enabled product opportunities, today expressed...

PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

Mon, 13 Apr 2026 08:00:00 -0400

Patent filing intended to strengthen PharmaTher's peptide formulation capabilities for PharmaPatch™ while complementing PatchPrint™ as part of the Company's broader microneedle patch development and commercialization strategyToronto, Ontario--(Newsfile Corp. - April 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it has submitted U.S. provisional patent application No. 64/034,315 to the United States...

PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

Thu, 26 Mar 2026 08:00:00 -0400

Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including peptide patches, branded wellness patches, manufacturing systems and commercial partnerships.Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it submitted a provisional...

PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

Tue, 03 Mar 2026 08:00:00 -0500

Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of psychedelics and peptides, today announced a strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market, building on the Company's ketamine and psychedelics patch development achievements and its recent entry...